Stocks & Investing
Stocks and Investing
Stocks and Investing
Wed, June 21, 2023
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
Raghuram Selvaraju Reiterated (URGN) at Strong Buy and Held Target at $23 on, Jun 21st, 2023
Raghuram Selvaraju of HC Wainwright & Co., Reiterated "UroGen Pharma Ltd." (URGN) at Strong Buy and Held Target at $23 on, Jun 21st, 2023.
Raghuram has made no other calls on URGN in the last 4 months.
There is 1 other peer that has a rating on URGN. Out of the 1 peers that are also analyzing URGN, 0 agree with Raghuram's Rating of Hold.
This is the rating of the analyst that currently disagrees with Raghuram
- Leland Gershell of "Oppenheimer" Reiterated at Buy and Held Target at $22 on, Monday, May 15th, 2023
